Gustave Roussy, the first cancer research and treatment center in France and Europe, maintains its position in the top 5 hospitals for oncology globally

For the fifth consecutive year, Newsweek magazine has ranked Gustave Roussy among the top five hospitals for oncology worldwide, highlighting its outstanding performance in both patient care and research.

First in France, first in Europe, and fourth globally. The World’s Best Specialized Hospital ranking, published by Newsweek magazine in collaboration with Statista, ranks the best hospitals worldwide each year, divided into 12 categories. For the 2025 edition, Gustave Roussy has been ranked fourth among the best hospitals for oncology globally for the second year in a row.

This ranking was established based on the results of an online survey sent to thousands of renowned health experts and on patient-reported quality indicators.

Continuity in excellence

“Being ranked for the second year in a row fourth best oncology hospital globally is a recognition of the outstanding commitment of Gustave Roussy’s healthcare providers, who are fully committed to curing cancer in the 21st century. It is Gustave Roussy’s continuity in excellence that is acknowledged here, in care as well as in research”, declares Prof. Fabrice Barlesi, Gustave Roussy’s General Director.

The Institute, which will celebrate in November the 150th birthday of its founder’s birth, has become over the last decades a major and innovative actor in global oncology. Its role in the emergence and development of precision medicine, immunotherapy, or radiotherapy is acknowledged today.

The commitment of all healthcare providers working every day at Gustave Roussy, 15 of whom are on the Clarivate / Web of Science list of the most highly cited researchers globally, is flawless. The expertise and work of the Institute's physician-researchers, some of whom lead international learned societies, are regularly recognized at international congresses. Gustave Roussy is also recognized for its ability to conduct early trials, thanks to its Department of Therapeutic Innovation and Early Trials (DITEP), one of the largest in Europe.

“This fourth place commits us once again to our patients, to keep offering them excellence in oncology, and to work relentlessly to find new therapeutic pathways. Gustave Roussy is driven by the desire to ensure that as many people as possible benefit from the advances developed within its walls, through the dissemination of these advances at international congresses or the industrialization of its discoveries. Major investments have been made in recent years in this direction, to build a true campus dedicated to oncology and precision medicine around the Institute and the Paris-Saclay Cancer Cluster. 2024 will mark the start of work on a brand new research center for Gustave Roussy, which, when inaugurated in 2028, will cover 32,800 square meters”, concludes Prof. Fabrice Barlesi.

► Consult the ranking and its methodology